Intuitive Surgical, Inc.'s Growing Pains Still Painful

Vague guidance and higher expenses spoil a relief rally from this robot champion.

Jan 27, 2014 at 6:30PM

There's a lot about the Intuitive Surgical (NASDAQ:ISRG) story that feels familiar. Whether you look at recent examples, like transcatheter heart valves and left ventricular assist devices, or more distant historical examples, like stents, Intuitive Surgical has followed that familiar pattern of "you don't get it ... this changes everything and valuations don't matter" to "oh no! It's not growing to infinity!"

I don't mean to flippant about what has surely been a harrowing couple of years for Intuitive Surgical shareholders. The good news is that clinical data continue to support the argument that robotic surgery deserves its place at the table and has value to offer alongside the minimally invasive tools and approaches advanced by Johnson & Johnson (NYSE:JNJ) and Covidien (NYSE:COV). The bad news is that the stock gets whipsawed as short term-focused analysts and institutions obsess over the next year or the next quarter and cannot look at the longer term.  

Fourth quarter results remind us that details (and guidance) matter
Investors reacted with a great deal of relief when Intuitive Surgical gave an early peek at revenue, disclosing that fourth quarter revenue would be about 5% higher than analysts were expecting.

When the actual results (and guidance) arrived, though, the response wasn't as positive. Revenue fell 5% as the company guided, with system sales down 23% on a 46% decline in US system sales. Instrument revenue was up 6% on top of 12% underlying procedure growth, while service revenue rose 14%.

Gross margin fell almost three points (more than 150bp below expectation), while operating income declined 16%. Operating income actually exceeded expectations as the company spent less than expected on R&D and SG&A.

Vague Guidance Plays To The Street's Fears
Intuitive Surgical is in a pretty precarious position. Investors are nervous about the slowing trends in prostate and hysterectomy procedures, and worried that a seemingly constant drumbeat of "surgical robots aren't worth the money" in the media will hurt prospects for adoption in cholecystectomy and other general surgical procedures.

Management could have perhaps calmed things a bit with reassuring guidance, but instead said that conditions were too uncertain to give revenue or system sales guidance. The guidance for 9% to 12% procedure volume growth fit expectations, but the guidance for double-digit growth in operating expenses was a real surprise.

Playing Short Versus Long
Coming out of this quarter, it looks like the Street is really worried that Intuitive is going to have to spend more money on an ongoing basis to support the sales effort and improve reimbursement in markets around the world.

Analysts also seem to be worried about the impact of the Si-e system. This system carries a lower ASP (about 20% to 33% lower) and there is a fear that it will produce a less profitable mix of business (less complex cases). Herein is one of the big short-versus-long-term issues with this company – over the long term, I think it is a very good idea for Intuitive to target additional outpatient/ambulatory minimally invasive markets. These are areas where J&J and Covidien are already strong and it would be an important part of penetrating the company's overall addressable market, even if it has margin consequences in the short term.

The Bottom Line
Both JNJ and Covidien had solid quarters in their respective surgical businesses (JNJ up 4%, Covidien up 8% operationally), and Stryker also reported good growth in hospital demand for instruments and endoscopes. In other words, I think the underlying environment for less invasive surgery is healthy.

I likewise expect the current fuss over safety and cost-effectiveness to blow over – complications are rising as procedures increase, but the rate-per-procedure is improving. Likewise, while a few articles in JAMA attacking the economics of robotic surgery got a lot of attention, lesser-publicized articles have suggested that the economics for robotic surgery are positive for hospitals and payers.

One stock pick investors need to watch in 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Covidien, Intuitive Surgical, and Johnson & Johnson. The Motley Fool owns shares of Intuitive Surgical and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information